Search Results Search Sort by RelevanceMost Recent Policy Forum Nov 2004 Genetic Samples and Genetic Philanthropy Michael E. Berens, PhD and Gary E. Marchant, PhD, JD Genetic research is threatened by lack of samples, and public policy should be developed to encourage public participation. Read in: English Virtual Mentor. 2004; 6(11):509-511. doi: 10.1001/virtualmentor.2004.6.11.pfor2-0411. State of the Art and Science Jan 2003 How to Change Routes of Administration of Opioids Audiey Kao, MD, PhD A formula designed to help physicians select appropriate dosage when changing the route of opioid administration for pain management. Read in: English Virtual Mentor. 2003; 5(1):19-20. doi: 10.1001/virtualmentor.2003.5.1.cprl1-0301. Viewpoint Apr 2004 Global Health Equity Paul Farmer, MD, PhD A physician describes his work with Partners in Health and his public health advocacy work in Haiti and encourages physicians to take health care equity to the global arena. Read in: English Virtual Mentor. 2004; 6(4):191-193. doi: 10.1001/virtualmentor.2004.6.4.oped1-0404. Viewpoint Dec 2004 Does Evidence-Based Medicine Offer Fair Benefits for All? Wendy A. Rogers, PhD, FRACGP Evidence-based medicine has the potential to offer objectivity and standardized practices into an often subjective decision-making process. Read in: English Virtual Mentor. 2004; 6(12):570-573. doi: 10.1001/virtualmentor.2004.6.12.oped1-0412. Policy Forum Jul 2024 How Should the Use of Opioids Be Regulated to Motivate Better Clinical Practice? Ellen L. Edens, MD, MPE, MA, Gabriela Garcia Vassallo, MD, and Robert Heimer, PhD Reconsider regulatory and clinical frameworks for prescribing long-term opioid therapy for pain and prescribing opioids to treat OUD. Read in: English AMA J Ethics. 2024; 26(7):E551-561. doi: 10.1001/amajethics.2024.551. In the Literature Jul 2024 How Should Harm Reduction Strategies Differ for Adolescents and Adults? Brady J. Heward, MD, Amy M. Yule, MD, and Peter R. Jackson, MD Recent increases in adolescent mortality from overdose have outpaced increases in mortality in members of the general population. Read in: English AMA J Ethics. 2024; 26(7):E534-545. doi: 10.1001/amajethics.2024.534. Case and Commentary Jul 2024 How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD? Kathryn A. Dong, MD, MSc and Katherine M. Duthie, PhD, HEC-C Severe withdrawal, risk of patient-initiated discharge, and some inpatients’ uses of substances prompt questions considered in this commentary. Read in: English AMA J Ethics. 2024; 26(7):E512-519. doi: 10.1001/amajethics.2024.512. Case and Commentary Jul 2024 When Medication Treatment for Opioid Use Disorder Gets Disrupted by Extra-Clinical Variables, How Should Clinicians Respond? Taleed El-Sabawi, JD, PhD and Kelly Gillespie, JD, PhD, RN Clinicians caring for patients with OUD should plan for possible disruptions of treatment caused by arrests and pretrial confinements. Read in: English AMA J Ethics. 2024; 26(7):E520-526. doi: 10.1001/amajethics.2024.520. Viewpoint Jul 2024 Opioid Epidemic Grief and Characterological Harm Reduction Christy A. Rentmeester, PhD Becoming callous, bitter, or resentful are harms we can suffer when grieving losses, especially at epidemic scale. Read in: English AMA J Ethics. 2024; 26(7):E587-590. doi: 10.1001/amajethics.2024.587. History of Medicine Jul 2024 Drawing on Black and Queer Communities’ Harm Reduction Histories to Improve Overdose Prevention Strategies and Policies Sterling Johnson, JD, MA and Kimberly L. Sue, MD, PhD Black and queer community-based harm reduction practices can help guide development and implementation of anti-overdose interventions. AMA J Ethics. 2024; 26(7):E580-586. doi: 10.1001/amajethics.2024.580. Pagination First page « First Previous page ‹ Previous … Page 24 Page 25 Page 26 Page 27 Page 28 Page 29 Current page 30 Page 31 Page 32 Next page Next › Last page Last »
Policy Forum Nov 2004 Genetic Samples and Genetic Philanthropy Michael E. Berens, PhD and Gary E. Marchant, PhD, JD Genetic research is threatened by lack of samples, and public policy should be developed to encourage public participation. Read in: English Virtual Mentor. 2004; 6(11):509-511. doi: 10.1001/virtualmentor.2004.6.11.pfor2-0411.
State of the Art and Science Jan 2003 How to Change Routes of Administration of Opioids Audiey Kao, MD, PhD A formula designed to help physicians select appropriate dosage when changing the route of opioid administration for pain management. Read in: English Virtual Mentor. 2003; 5(1):19-20. doi: 10.1001/virtualmentor.2003.5.1.cprl1-0301.
Viewpoint Apr 2004 Global Health Equity Paul Farmer, MD, PhD A physician describes his work with Partners in Health and his public health advocacy work in Haiti and encourages physicians to take health care equity to the global arena. Read in: English Virtual Mentor. 2004; 6(4):191-193. doi: 10.1001/virtualmentor.2004.6.4.oped1-0404.
Viewpoint Dec 2004 Does Evidence-Based Medicine Offer Fair Benefits for All? Wendy A. Rogers, PhD, FRACGP Evidence-based medicine has the potential to offer objectivity and standardized practices into an often subjective decision-making process. Read in: English Virtual Mentor. 2004; 6(12):570-573. doi: 10.1001/virtualmentor.2004.6.12.oped1-0412.
Policy Forum Jul 2024 How Should the Use of Opioids Be Regulated to Motivate Better Clinical Practice? Ellen L. Edens, MD, MPE, MA, Gabriela Garcia Vassallo, MD, and Robert Heimer, PhD Reconsider regulatory and clinical frameworks for prescribing long-term opioid therapy for pain and prescribing opioids to treat OUD. Read in: English AMA J Ethics. 2024; 26(7):E551-561. doi: 10.1001/amajethics.2024.551.
In the Literature Jul 2024 How Should Harm Reduction Strategies Differ for Adolescents and Adults? Brady J. Heward, MD, Amy M. Yule, MD, and Peter R. Jackson, MD Recent increases in adolescent mortality from overdose have outpaced increases in mortality in members of the general population. Read in: English AMA J Ethics. 2024; 26(7):E534-545. doi: 10.1001/amajethics.2024.534.
Case and Commentary Jul 2024 How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD? Kathryn A. Dong, MD, MSc and Katherine M. Duthie, PhD, HEC-C Severe withdrawal, risk of patient-initiated discharge, and some inpatients’ uses of substances prompt questions considered in this commentary. Read in: English AMA J Ethics. 2024; 26(7):E512-519. doi: 10.1001/amajethics.2024.512.
Case and Commentary Jul 2024 When Medication Treatment for Opioid Use Disorder Gets Disrupted by Extra-Clinical Variables, How Should Clinicians Respond? Taleed El-Sabawi, JD, PhD and Kelly Gillespie, JD, PhD, RN Clinicians caring for patients with OUD should plan for possible disruptions of treatment caused by arrests and pretrial confinements. Read in: English AMA J Ethics. 2024; 26(7):E520-526. doi: 10.1001/amajethics.2024.520.
Viewpoint Jul 2024 Opioid Epidemic Grief and Characterological Harm Reduction Christy A. Rentmeester, PhD Becoming callous, bitter, or resentful are harms we can suffer when grieving losses, especially at epidemic scale. Read in: English AMA J Ethics. 2024; 26(7):E587-590. doi: 10.1001/amajethics.2024.587.
History of Medicine Jul 2024 Drawing on Black and Queer Communities’ Harm Reduction Histories to Improve Overdose Prevention Strategies and Policies Sterling Johnson, JD, MA and Kimberly L. Sue, MD, PhD Black and queer community-based harm reduction practices can help guide development and implementation of anti-overdose interventions. AMA J Ethics. 2024; 26(7):E580-586. doi: 10.1001/amajethics.2024.580.